Jain P, et al. - In a single-center, single arm, open-label, phase 2 study, ibrutinib with rituximab (IR) was tested as a treatment option for patients with relapsed or refractory mantle cell lymphoma (RR-MCL). Researchers report the long-term outcome and safety profile as assessed during the median follow-up time of 47 months (range 1–52 months). The median duration of treatment was 16 months (range 1–53 months) and median number of treatment cycles was 17 (range 1–56). The observed median progression-free survival was 43 months. They found that in a subset of patients with RR-MCL, particularly those with low Ki67%, durable remissions could be achieved with IR treatment.